Morgan Stanley Otonomy, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.25 - $2.24 $1,891 - $16,943	7,564 Added 25.32%	37,440 $11,000
Q2 2022 Oct 27, 2022	SELL	$1.72 - $2.51 $765 - $1,116	-445 Reduced 1.47%	29,876 $62,000
Q2 2022 Aug 15, 2022	SELL	$1.72 - $2.51 $765 - $1,116	-445 Reduced 1.47%	29,876 $62,000
Q1 2022 Oct 27, 2022	BUY	$1.72 - $2.47 $765 - $1,099	445 Added 1.49%	30,321 $73,000
Q1 2022 May 13, 2022	SELL	$1.72 - $2.47 $189,019 - $271,440	-109,895 Reduced 78.38%	30,321 $73,000
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.31 $185,881 - $254,074	109,989 Added 363.88%	140,216 $292,000
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.2 $36,876 - $66,499	30,227 New	30,227 $58,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.